New data shows Genentech's potential Spinraza competitor inching forward - STAT

New data shows Genentech's potential Spinraza competitor inching forward - STAT

STAT Plus: New data shows Genentech’s potential competitor for Spinraza inching forward

By KATE SHERIDAN

PAUL SAKUMA/AP

The new data shows that the drug, risdiplam, could help children with spinal muscular atrophy sit up and move more easily.

READ MORE